137795-17-6

(±)-WIN 55,212 is a racemic mixture of the cannabinoid (CB) receptor 1 (CB₁) and CB₂ agonist (+)-WIN 55,212-2 and the CB₂ neutral antagonist (?)-WIN 55,212-3 .¹ It inhibits electrically induced contractions in mouse vas deferens preparations (IC₅₀ = 0.006 μM) and reduces prostaglandin (PG) synthesis by 35% in mouse brain microsomes when used at a concentration of 30 μM.² (±)-WIN 55,212 decreases acetylcholine-induced writhing in mice with an ED₅₀ value of 0.25 mg/kg. It induces hypolocomotion, analgesia, hypothermia, and catalepsy in mice (ED₅₀s = 1.09, 0.5, 3.01 and 6.8 mg/kg, respectively).³

1. Savinainen, J.R., Kokkola, T., Salo, O.M.H., et al. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB₂ receptor Br. J. Pharmacol. 145,636-645(2005).
2. D'Ambra, T.E., Estep, K.G., Bell, M.R., et al. Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor J. Med. Chem. 35,124-135(1992).
3. Fan, F., Compton, D.R., Ward, S., et al. Development of cross-tolerance between Δ⁹-tetrahydrocannabinol, CP 55,940 and WIN 55,212 J. Pharmacol. Exp. Ther. 271(3),1383-1390(1994).